Though more clarity is to emerge on Israeli drug-maker Taro's operations, Sun Pharma has revised its guidance on topline growth to 35 per cent from the earlier projection of 20 per cent. Sun is still trying to get a handle on Taro's business and there were plans for “incremental investment” in Taro's facilities in Israel and Canada.
New investments in Taro's plants were approved after Sun took over and it would be on similar lines as it happens in Sun. Taro has shut down its Ireland plant and some equipment has been transferred to the Canada and Israel plants. The Ireland plant — that had also become a bone of contention between the two companies when they were locked in litigation — is not in “usable form”.
Taro brings to the table about 150 abbreviated new drug applications (ANDA – that allows sale in the US), and a pipeline of drugs that Sun does not have the capacity to make or does not have the time to bring to the market. Sun, on its part, will take Taro products to new geographies and will also look to strengthen Taro's pipeline by undertaking clinical studies on products.
crackcrack| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1847.30 |
| Dr. Reddys Lab | 1293.25 |
| Cipla | 1347.70 |
| Zydus Lifesciences | 938.90 |
| Lupin | 2377.90 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: